Publication: Mitosin, a novel marker of cell proliferation and early recurrence in intracranial meningiomas
Authors
Konstantinidou, A.E. ; Korkolopoulou, P. ; Kavantzas, N. ; Mahera, H. ; Thymara, I. ; Kotsiakis, X. ; Perdiki, M. ; Patsouris, Efstratios ; Davaris, P.
item.page.secondaryauthor
item.page.director
Publisher
Murcia : F. Hernández
publication.page.editor
publication.page.department
DOI
item.page.type
info:eu-repo/semantics/article
Description
Abstract
The expression of mitosin, a novel
proliferation-associated molecule was evaluated
immunohistochemically in a consecutive series of 47
patients with primary intracranial benign and atypical
meningiomas. Mitosin expression was correlated with
proliferation markers Ki-67 (MIB-1), proliferating cell
nuclear antigen (PCNA), topoisomerase IIa (TopoIIa)
and mitotic index, as well as with standard
clinicopathological parameters and patient outcome.
Seven tumors recurred (14.8%) following gross total
resection, within a follow-up period ranging from 21 to
108 months (median 60 months). The higher
proliferation indices were obtained with mitosin and
PCNA and the lower ones with TopoI?a. Mitosin
labeling index (LI) ranged from 0.1 to 57% (median
3%), with a significant overlapping of values between
grades. A significant positive correlation was shown
between mitosin LI on the one hand and Ki-67 LI
(p<0.001), or the mitotic index (p=0.027) on the other.
The incidence of recurrence was higher in cases with a
mitosin LI higher than 3% (p=0.048). Univariate
analysis disclosed mitosin LI (p=0.033) along with the
mitotic index (p=0.024) and tumor size (p=0.028) as
significant predictors of shortened recurrence-free
survival. In multivariate analysis, the labeling indices of
mitosin (p=0.035) and Ki-67 (p=0.032), along with
tumor size, were shown to provide independent prognostic information, beyond that obtained by
standard clinical and pathological parameters. However,
as indicated by factor analysis, the prognostic
information yielded by mitosin was superior to that
provided by the remaining proliferation markers
(p=0.041). We conclude that mitosin immunohistochemical
expression, although failing to discriminate
between benign and atypical meningiomas, may be of
use as a novel cell proliferation marker and as a
predictor of tumor recurrence.
publication.page.subject
Citation
item.page.embargo
Ir a Estadísticas
Sin licencia Creative Commons.